Madison Clarke
The hepatitis B vaccine is made using baker's yeast, and residual quantities of yeast proteins are contained in the final product. Recombivax HB, Engerix-B, and Heplisav-B are examples of vaccines that contain yeast cell culture remnants. The use of recombinant DNA technology in the development of hepatitis B vaccines has eliminated the need for blood-derived antigens, making the vaccine safer and more scalable.
| Characteristics | Values |
|---|---|
| Vaccine Name | Recombivax HB |
| Disease | Hepatitis B |
| Yeast Type | Baker's yeast (Saccharomyces cerevisiae) |
| Yeast Protein Content | No more than 1 mg per ml |
| Allergic Reactions | Rare (about 1 case per 600,000 doses) |
| Safety | Safe even for subjects with pre-existing anti-yeast IgE antibodies |
| Type of Vaccine | Subunit, recombinant, and synthetic |
Explore related products
What You'll Learn
- The hepatitis B vaccine is made using baker's yeast
- Recombivax HB is a vaccine that contains yeast cell culture remnants
- Yeast-derived hepatitis B vaccines are safe and do not cause allergic reactions
- Hepatitis B vaccines are made using recombinant DNA technology
- Yeast proteins in hepatitis B vaccines do not cause type I or type III allergic reactions
The hepatitis B vaccine is made using baker's yeast
The use of baker's yeast in the production of the hepatitis B vaccine has several advantages. Firstly, it overcomes the limitations of using plasma from human carriers of the hepatitis B virus, which has a limited supply and requires stringent purification processes to remove infectious agents. By using recombinant yeast, the vaccine can be produced in large quantities with the correct amino acid sequence and conformational structure to stimulate an appropriate immune response.
The hepatitis B vaccine produced from baker's yeast has been shown to be safe and effective in both animal and human tests. It was first licensed for general use in Germany and the United States in 1986 and has since become a widely used vaccine for the prevention of hepatitis B virus infection.
The development of the yeast-derived hepatitis B vaccine has also paved the way for new vaccines to be made using recombinant technology. This technology has been applied to create other vaccines, such as mucosal vaccines, and continues to be an important area of research in vaccine development.
Overall, the use of baker's yeast in the production of the hepatitis B vaccine has been a significant advancement in the field of medicine, providing a safe, effective, and economically feasible vaccine for the prevention of a serious disease.
Understanding Viral Vector Vaccines: Host Synthesis of Antigens
You may want to see also
Explore related products
Recombivax HB is a vaccine that contains yeast cell culture remnants
For newborns up to 19-year-olds, the regimen consists of three 0.5 mL doses, administered on a 0-, 1-, and 6-month schedule. For 11 to 15-year-olds, there is an alternative regimen of two 1.0 mL doses, given on a 0- and 4- to 6-month schedule. For those aged 20 and above, the regimen consists of three 1.0 mL doses, given on a 0-, 1-, and 6-month schedule. The preferred site for intramuscular injection is the deltoid muscle for adults, adolescents, and children over 1 year old with a deltoid large enough for the injection. For infants younger than 1 year, the preferred site is the anterolateral aspect of the thigh.
Recombivax HB should not be administered in the gluteal region, as this has resulted in lower seroconversion rates. It is also important to note that this vaccine may not prevent hepatitis B infection in individuals with an unrecognized hepatitis B infection at the time of vaccination. In healthy infants and children up to 10 years of age, injection site reactions and systemic adverse reactions have been reported following vaccinations. The most frequently reported systemic adverse reactions were irritability, fever, diarrhea, fatigue/weakness, diminished appetite, and rhinitis.
Vaccines vs Antibiotics: A Quick Comparison
You may want to see also
Explore related products
Yeast-derived hepatitis B vaccines are safe and do not cause allergic reactions
Yeast-derived hepatitis B vaccines are considered safe for use, despite some reports of adverse reactions. The vaccines are made using baker's yeast, with residual quantities of yeast proteins contained in the final product. For example, Engerix-B and Heplisav-B contain no more than 5 mg per ml, while Recombivax HB contains no more than 1 mg per ml of yeast proteins.
Despite the presence of yeast proteins, studies have shown that yeast-derived hepatitis B vaccines do not cause type I or type III allergic reactions. Volunteers inoculated with three doses of the vaccine at monthly intervals showed no rise in IgE antibodies against Saccharomyces cerevisiae antigens or IgG antibodies against Candida albicans antigens. This indicates that yeast proteins in the vaccines are unlikely to trigger allergic responses.
However, it is important to note that severe allergic reactions have been reported after receiving the hepatitis B vaccine, albeit rarely, with approximately 1 case per 600,000 doses. These reactions can include hives, difficulty breathing, low blood pressure, swelling of the face and throat, a fast heartbeat, dizziness, and weakness. Nonetheless, the occurrence of these reactions is not attributed to an allergy to yeast proteins.
Furthermore, large-scale studies have suggested an increased risk of developing multiple sclerosis (MS) following the hepatitis B vaccine, with a potential link to molecular mimicry as a possible mechanism. However, molecular mimicry is unlikely to be the sole explanation for autoimmune responses, and more research is needed to fully understand the relationship between the vaccine and MS.
In summary, while yeast-derived hepatitis B vaccines may contain trace amounts of yeast proteins, they are generally safe and do not cause allergic reactions specifically due to yeast antigens. The occurrence of severe allergic reactions is rare and not directly linked to yeast proteins. As such, these vaccines are suitable for most individuals, except for those with a specific allergy to yeast, in which case the PREHEVBRIO vaccine, which does not contain yeast, is recommended.
Vaccination Policy: A Collective Action Problem
You may want to see also
Explore related products
Hepatitis B vaccines are made using recombinant DNA technology
Recombinant DNA technology has been used to develop hepatitis B vaccines. The first hepatitis B vaccine was approved in the United States in 1981, and a recombinant version came to market in 1986. This was the first human vaccine produced using recombinant DNA methods. The recombinant vaccine is based on a hepatitis B surface antigen (HBsAg) gene inserted into yeast (Saccharomyces cerevisiae) cells. The HBsAg gene is expressed in yeast cells, and the resulting HBsAg is assembled into 22-nm–diameter lipoprotein particles. The HBsAg is purified to greater than 99% for protein, and the purified protein is sterile filtered and then coprecipitated with alum to form the bulk vaccine. The vaccine contains no detectable yeast DNA but may contain up to 1% yeast protein.
The development of the recombinant hepatitis B vaccine was driven by the need to find an alternative to the plasma-derived vaccine, which was expensive and had limited supply due to the availability of infected plasmas. There were also theoretical safety concerns associated with the plasma from HBV carriers who may be co-infected with other pathogens such as HIV. Recombinant DNA technology enabled the production of unlimited supplies of the hepatitis B vaccine, making it feasible for worldwide use.
Hepatitis B vaccines are available either as a single preparation (monovalent- Engerix B, HB-Vax-II) or in combined form (multivalent-Infanrix hexa, Hexaxim, Pediarix, Vaxelis, and Twinrix). The vaccine is generally considered safe for use during pregnancy or while breastfeeding and has not been linked to Guillain-Barré syndrome. Serious side effects are very rare. The World Health Organization (WHO) has recommended universal hepatitis B vaccination, and many countries have implemented routine vaccination programs for newborns, infants, children, and high-risk groups to reduce the spread of the virus.
The hepatitis B vaccine has been shown to be heat stable, which is advantageous for storage and transportation, especially in countries where "cold chains" are not always available. Studies have demonstrated that the immunogenicity of the recombinant DNA hepatitis B vaccine stored at 37°C for up to one week or month, or at 45°C for one week, is comparable to that of the vaccine stored at the recommended temperature of 4°C.
Vaccine Route and Site: What's the Right Combo?
You may want to see also
Explore related products
Yeast proteins in hepatitis B vaccines do not cause type I or type III allergic reactions
Hepatitis B vaccines are made using baker's yeast, and residual quantities of yeast proteins are contained in the final product. Engerix-B and Heplisav-B contain no more than 5 mg per ml, while Recombivax HB contains no more than 1 mg per ml of yeast proteins. The yeast-recombinant hepatitis B vaccine is derived from a culture of Saccharomyces cerevisiae, and there is a theoretical concern that the administration of a vaccine prepared in yeast could induce allergic reactions to yeast proteins.
However, studies have shown that yeast proteins in hepatitis B vaccines do not cause type I or type III allergic reactions. Volunteers were inoculated with three doses of yeast-derived hepatitis B vaccines at monthly intervals and compared with plasma-derived vaccines. Before and after immunizations, blood samples were tested for the presence of IgE or IgG antibodies against yeast antigens related to Saccharomyces cerevisiae and Candida albicans. No rise in IgE antibodies against Saccharomyces cerevisiae antigens or in IgG antibodies against Candida albicans antigens was found.
Furthermore, prior to vaccine licensure, clinical trials were performed to address whether residual yeast proteins in the vaccines could induce anaphylaxis, including testing for IgE anti-yeast antibody levels. While 1-2% of subjects had anti-yeast IgE antibodies before immunization, they demonstrated no significant rise in IgE after HBV. This suggests that yeast-derived hepatitis B vaccines are safe even in subjects with pre-existing anti-yeast IgE antibodies.
While severe adverse events have been reported infrequently in adults and rarely in infants and children given the hepatitis B vaccine, these reactions are rare and do not appear to be caused by an allergy to yeast proteins.
Equine Vaccines: 5-Way Protection for Horses
You may want to see also
Frequently asked questions
The hepatitis B vaccine.
Hepatitis B vaccines are made using baker's yeast, also known as Saccharomyces cerevisiae, and residual quantities of yeast proteins are contained in the final product.
Yes, yeast-derived hepatitis B vaccines are safe, even in subjects with pre-existing anti-yeast IgE antibodies.
